Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913459
rs121913459
0.020 GeneticVariation BEFREE Purinostat mesylate efficiently attenuated Ph<sup>+</sup> B-ALL progression and significantly prolonged the survival both in BL-2 secondary transplantation model with clinical patient symptoms of Ph<sup>+</sup> B-ALL, <i>BCR-ABL(T315I)</i>-induced primary B-ALL mouse model, and PDX model derived from patients with relapsed Ph<sup>+</sup> B-ALL post TKI treatment. 31439580

2019

dbSNP: rs121913459
rs121913459
0.020 GeneticVariation BEFREE Using BCR-ABL-expressing myelogenous and lymphoid cell lines and mouse models of CML and B-cell acute lymphoblastic leukemia (B-ALL) induced by wild-type BCR-ABL or T315I mutant-BCR-ABL, we evaluated the inhibitory effects of omacetaxine on CML and B-ALL. 19322212

2009

dbSNP: rs12430881
rs12430881
0.010 GeneticVariation BEFREE In the present study, a strong risk of B-cell acute lymphoblastic leukemia was associated with rs35958982 and rs12430881 polymorphisms. 31565544

2019

dbSNP: rs2393732
rs2393732
0.010 GeneticVariation BEFREE The seven SNPs were associated with risk of pre-B ALL in younger children; however, rs2393732, rs2393782, rs2893881, and rs4948488 were not associated with susceptibility in older children and adolescents. 31227872

2019

dbSNP: rs35958982
rs35958982
0.010 GeneticVariation BEFREE In the present study, a strong risk of B-cell acute lymphoblastic leukemia was associated with rs35958982 and rs12430881 polymorphisms. 31565544

2019

dbSNP: rs3780135
rs3780135
0.010 GeneticVariation BEFREE At locus 9p13.2 (rs3780135, <i>PAX5</i>), the risk allele frequency was significantly higher in B-ALL subjects than ancestral allele frequency (OR = 2.17, CI [1.37-3.43], <i>P</i> = 0.000). 31565544

2019

dbSNP: rs4948488
rs4948488
0.010 GeneticVariation BEFREE The seven SNPs were associated with risk of pre-B ALL in younger children; however, rs2393732, rs2393782, rs2893881, and rs4948488 were not associated with susceptibility in older children and adolescents. 31227872

2019

dbSNP: rs13107325
rs13107325
0.010 GeneticVariation BEFREE The variant, rs13107325, is almost exclusive of European populations and is one of the most pleiotropic variants of the genome, being associated at genome-wide significant level with several additional traits, such as body mass index, Crohn's disease, blood pressure related-traits, and serum levels of manganese, N-terminal pro-B-type natriuretic peptide and HDL-cholesterol. 28557351

2018

dbSNP: rs1057519743
rs1057519743
0.010 GeneticVariation BEFREE The prevalence of CRLF2 overexpression, CRLF2-P2RY8 fusion, CRLF2 F232C mutation, and JAK2 and IL7R mutational status were analyzed, and the prognostic impact of CRLF2 overexpression and P2RY8-CRLF2 on B-ALL was evaluated by assessing their influence on overall survival and event-free survival. 27637012

2017

dbSNP: rs11980379
rs11980379
0.010 GeneticVariation BEFREE The previously reported pediatric B-ALL GWAS variant, rs11980379 (<i>IKZF1</i>), replicated in B-ALL pediatric patients (OR<sub>meta</sub> = 2.3; 95% CI, 1.5, 3.7; <i>P</i><sub>meta</sub> = 1.0 × 10<sup>-9</sup>), with evidence of heterogeneity (<i>P</i> = .02) between males and females. 29296818

2017

dbSNP: rs1346944271
rs1346944271
0.010 GeneticVariation BEFREE Furthermore, we show that primary ALL mononuclear cells harboring the JAK2 R938Q mutation display reduced sensitivity to the JAK1/2 ATP-competitive inhibitor ruxolitinib in vitro, compared to ALL cells that carry a more common JAK2 pseudokinase domain mutation. 29025600

2017

dbSNP: rs189434316
rs189434316
0.010 GeneticVariation BEFREE We identified 1 novel variant, rs189434316, significantly associated with odds of normal cytogenetic B-ALL (odds ratio from meta-analysis [OR<sub>meta</sub>] = 3.7; 95% confidence interval [CI], 2.5, 6.2; <i>P</i> value from meta-analysis [<i>P</i><sub>meta</sub>] = 6.0 × 10<sup>-9</sup>). 29296818

2017

dbSNP: rs62527607
rs62527607
0.010 GeneticVariation BEFREE The prevalence of the T-allele of rs62527607 [GT] SNP in childhood T-ALL and pre-B-ALL was 28.3% and 11.2%, respectively. 27372260

2017

dbSNP: rs156697
rs156697
0.010 GeneticVariation BEFREE This study found no significant association between Pre-B ALL and GSTO1 A140D and GSTO2 N142D polymorphisms. 25726706

2015

dbSNP: rs4925
rs4925
0.010 GeneticVariation BEFREE This study found no significant association between Pre-B ALL and GSTO1 A140D and GSTO2 N142D polymorphisms. 25726706

2015

dbSNP: rs4958351
rs4958351
0.010 GeneticVariation BEFREE Patients with GRIA1 rs4958351 AA/AG genotype showed significantly reduced risk to ASP hypersensitivity compared to patients with GG genotype in the T-cell ALL subgroup (OR = 0.05 (0.01-0.26); p = 4.70E-04), while no such association was found in pre-B-cell ALL. 26457809

2015

dbSNP: rs866838052
rs866838052
0.010 GeneticVariation BEFREE This study found no significant association between Pre-B ALL and GSTO1 A140D and GSTO2 N142D polymorphisms. 25726706

2015

dbSNP: rs1800629
rs1800629
TNF
0.010 GeneticVariation BEFREE The presence of at least one A allele in TNF-α SNP rs1800629 should suggest a closer monitoring in B-cell acute lymphoblastic leukemia standard risk patients. 24798719

2014

dbSNP: rs1057519723
rs1057519723
0.010 GeneticVariation BEFREE This study provides clues in understanding the mechanism of JAK2 R683S (G) mutations caused B-ALL. 23748007

2013

dbSNP: rs1057519721
rs1057519721
0.010 GeneticVariation BEFREE In this study, we identify G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in MPNs) or JAK2 R683G (observed in B-ALL). 22271575

2012

dbSNP: rs529311209
rs529311209
0.010 GeneticVariation BEFREE In this study, we identify G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in MPNs) or JAK2 R683G (observed in B-ALL). 22271575

2012

dbSNP: rs77375493
rs77375493
0.010 GeneticVariation BEFREE In this study, we identify G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in MPNs) or JAK2 R683G (observed in B-ALL). 22271575

2012

dbSNP: rs121434592
rs121434592
0.010 GeneticVariation BEFREE Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. 20440266

2010

dbSNP: rs780634396
rs780634396
0.010 GeneticVariation BEFREE Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. 20440266

2010